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BACKGROUND: Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras
(K-Ras) mutation status. Current mandatory mutation testing for patient selection is limited to the K-Ras ‘hotspot’ codons 12 and 13.
METHODS: Colorectal tumours (n¼106) were screened for additional K-Ras mutations, phenotypes compared in transformation and
Ras GTPase activating assays and gene and pathway changes induced by individual K-Ras mutants identified by microarray analysis.
Taqman-based gene copy number and FISH analyses were used to investigate K-Ras gene amplification.
RESULTS: Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and
Arg164Gln (1 out of 106)) were identified. Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas
Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras. We additionally
identified a new K-Ras gene amplification event, present in approximately 2% of tumours.
CONCLUSIONS: The identification of mutations outwith previously described hotspot codons increases the K-Ras mutation burden in
colorectal tumours by one-third. Future mutation screening to facilitate optimal patient selection for treatment with EGFR-targeted
therapies should therefore be extended to codon 146, and in addition should consider the unique molecular signatures associated
with individual K-Ras mutations.
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Colorectal cancer accounts for approximately 15% of all cancers
diagnosed annually in the United Kingdom, and is a major cause of
death due to cancer, second only to lung and breast cancer (http://
info.cancerresearchuk.org/cancerstats/incidence).
The majority of colorectal tumours arise from adenomatous
polyps (adenomas), benign precursor lesions that develop from
normal colonic mucosa. However, fewer than 10% of colorectal
adenomas develop into invasive cancers and a number of
molecular mechanisms including epigenetic events, DNA mis-
match-repair defects, chromosomal rearrangements and mutations
in key oncogenes and tumour suppressor genes have been
suggested to regulate progression from adenoma to adeno-
carcinoma (de la Chapelle, 2004).
A genetic model for colorectal cancer highlighted key genes,
including the tumour suppressor genes adenomatous polyposis
coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the
progressive acquisition of mutations in which was proposed to
regulate the adenoma-carcinoma transition (Vogelstein et al,
1988). We subsequently refined this model (Smith et al, 2002),
highlighting a significant increase in K-Ras mutation frequency
in Dukes’ C tumours, suggesting that K-Ras mutation status
may be an important determinant of tumour progression. We
additionally used comparative genomic hybridisation (CGH)
analysis to identify common chromosomal aberrations in
colorectal tumours, and highlighted an amplification of the
region of chromosome 12p where the K-Ras gene is localised
(Leslie et al, 2003). We and others have shown that K-Ras
mutations are associated with significantly reduced survival in
colorectal cancer patients (Andreyev et al, 2001; Conlin et al,
2005), although previous data is not entirely consistent (Etienne-
Grimaldi et al, 2008; Winder et al, 2009). K-Ras mutation status
has recently been convincingly associated with response to the
new generation EGFR antagonists cetuximab (Erbitux) and
panitumumab (Vectibix), where response is preferentially
observed in wt K-Ras tumours (Lievre et al, 2006; Benvenuti
et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008;
Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van
Cutsem et al, 2009). K-Ras mutation testing is therefore increas-
ingly recommended to facilitate selection of the most appropriate
patients for treatment with EGFR antagonists (McNeill, 2008; van
Krieken and Tol, 2009).
K-Ras is a member of the highly homologous family of small
p21
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ssignals across the plasma membrane, principally by activation of
the RAS–RAF–MEK–ERK–MAPK signalling cascade (Figure 1;
(Barbacid, 1990)). Ras genes are the most frequently mutated
oncogenes in human cancer, where tumour-specific mutations lead
to the permanent activation of Ras signalling cascades, influencing
proliferation, differentiation and apoptosis (Bos, 1989). Previous
analyses of K-Ras mutations in human tumours have consistently
focussed on single-point mutations in codons 12, 13 and 61,
where mutation has been shown to result in reduced Ras GAP
GTPase activity, locking the protein in the active Ras-GTP
conformation (Ellis and Clark, 2000), although additional muta-
tions at codons 19, 22 and 146 have been described in single
colorectal tumour case reports (Orita et al, 1991; Miyakura et al,
2002; Akagi et al, 2007).
Ras proteins regulate signal transduction by activating a number
of downstream effector proteins, including the cytoplasmic
serine/threonine protein kinase B-Raf (Figure 1). B-Raf mutations
have also been identified in human cancers, including melanoma
and thyroid, ovarian and colorectal tumours, although mutation
frequency estimates in colorectal tumours vary from 1 to 20%,
and have been particularly associated with tumours deficient
in mismatch-repair activity (Wellbrock et al, 2004). The most
common B-Raf mutation is a T to A transversion, resulting in
a valine to glutamic acid substitution (V600E), present in
approximately 90% of B-Raf mutant tumours (Davies et al,
2002), which results in a 500-fold increase in in vitro kinase
activity and the induction of cell proliferation and transformation
(Wan et al, 2004). Although K-Ras and B-Raf mutations are
found in the same tumour types, they are thought to be mutually
exclusive (Wellbrock et al, 2004), providing distinct but related
mechanisms for the activation of K-Ras signalling pathways.
B-Raf mutation status has also recently been associated with
response to cetuximab and panitumumab where, like K-Ras,
clinical response is limited to wt B-Raf tumours (Di Nicolantonio
et al, 2008).
As K-Ras mutations in colorectal tumours are clearly important
biomarkers of tumour progression and patient survival and also
influence response to new generation EGFR antagonists, we have
used a variety of experimental approaches to further investigate
inter-individual differences in K-Ras mutation burden.
MATERIALS AND METHODS
Study participants
Patients (age range 45–80 years, median age 67 years, 64 males
and 42 females) undergoing surgery for colorectal cancer at
Ninewells Hospital, Dundee or Perth Royal Infirmary were invited
to participate in the study. All patients were Caucasian, had pre-
operative pathological confirmation of diagnosis (ICD-9 classifica-
tion 153.0–153.9, 154.0–154.1) and had no history of previous
cancer, inflammatory bowel disease, ulcerative colitis or diverti-
cular disease. Patient details have been described previously
(Smith et al, 2002). The study was approved by the Tayside
Committee on Medical Research Ethics and written informed
consent was obtained from all study participants.
DNA preparation
Primary colorectal tumour resection specimens were brought fresh
from theatre to pathology and tumours selected by an experienced
pathologist and stored in liquid nitrogen before analysis. Genomic
DNA for mutation analysis was extracted using the Wizard
Genomic DNA Purification Kit (Promega, Southampton, UK)
according to the manufacturer’s instructions. All study participants
provided a 10ml venous blood sample, which was stored in EDTA
blood containers at  201C. Genomic DNA was extracted from 200ml
of whole blood, using a QIAamp 96 spin blood kit (Qiagen, Crawley,
West Sussex, UK) according to the manufacturer’s instructions.
K-Ras and B-Raf mutation detection
Methods for K-Ras and B-Raf mutation detection and restriction
fragment length polymorphism (RFLP) analysis of mutation
frequencies are given in Appendix A.
Cell culture and transfection
The mouse embryonic fibroblast cell line NIH3T3 was obtained
from Cancer Research UK cell services. NIH3T3 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% calf serum unless otherwise stated, at 371C
in 5% CO2. Cells were transfected using Lipofectamine (Invitrogen,
Paisley, UK) according to the manufacturer’s instructions.
Mammalian expression plasmids
The pEF.6 plink and pEFHA wt K-Ras plasmids were kind gifts
from Professor Richard Marais (Institute of Cancer Research,
London, UK). Site-directed mutagenesis (SDM) was carried out on
the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit
(Agilent, South Queensferry, Edinburgh, UK) according to the
manufacturer’s instructions to generate the following K-Ras
mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and
R164Q, using the oligonucleotide primers described in Table 1.
K-Ras foci formation assays
NIH3T3 cells were seeded at 2.5 10
5 cells in 35mm culture dishes
and allowed to adhere overnight before transfection with 250ng of
either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the
following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N,
A146To rR 164Q. After 24h, cells were trypsinised and split (1:3)
between two 10cm
3 plates and grown in DMEM containing 5% calf
serum for 21 days, then fixed with methanol and stained with
0.5% (w/v) crystal violet. Foci greater then 5mm were counted
manually. All transfections were repeated three times and average
foci counts and standard deviations calculated.
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Figure 1 The Ras cycle. Ras proteins are key components of signal
transduction pathways leading from cell-surface receptors to the control of
cell proliferation, differentiation or death. Active Ras, where tumour-specific
mutations lock Ras in the GTP-bound conformation, stimulates the RAS–
RAF–MEK–ERK–MAP kinase signalling pathway.
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sRas GTPase activating assays
Ras activity was determined using a Ras activation assay kit
(Millipore, Watford, Hertfordshire, UK). Briefly, cells were
harvested 48h after transfection in an Mg-containing lysis buffer
(MLB). 500mg of cell lysate from each sample was incubated with
10mg of Raf-1 RBD agarose at 41C for 30min with gentle rocking.
After washing three times with MLB, the agarose beads were re-
suspended in 40ml of NuPage LDS sample buffer (Invitrogen), and
20ml of each sample separated on SDS-PAGE. A total of 30mgo f
whole-cell lysate was additionally separated by SDS–PAGE for the
analysis of total K-Ras expression.
Western blot analysis
Cells were lysed 48h after transfection with MKK lysis buffer
(20mM Tris-acetate, 1mM EDTA, 1% (v/v) Triton X-100, 1mM
EGTA, 0.1% (v/v) b-mercaptoethanol, 1mM sodium orthovana-
date, 1mM sodium pyrophosphate, 1mM sodium b-glycerophos-
phate, 5mM sodium fluoride and protease inhibitors). Cell lysates
were centrifuged at 13000r.p.m. for 15min at 41C and the soluble
fraction transferred to a fresh 1.5ml Eppendorf tube. Protein
concentration was determined using the Bio-Rad protein assay
(Bio-Rad, Hemel Hempstead, Hertfordshire, UK). For western blot
analysis, 30mg of each cell lysate was separated using the NuPage
electrophoresis system (12% pre-cast polyacrylamide gels, Invitro-
gen) and transferred to nitrocellulose membranes (Whatman,
Maidstone, Kent, UK). Membranes were probed with anti-K-Ras
(Merck, Nottingham, UK) and anti-actin (Santa Cruz Biotechnol-
ogy, Heidelberg, Germany) antibodies overnight at 41C. Secondary
horseradish peroxidase-conjugated antibodies (anti-mouse, Dako
or anti-goat, Santa Cruz Biotechnology) were applied for 1h at
room temperature before developing the membranes using
enhanced chemiluminescence.
RNA transcription profiling analysis
NIH3T3 cells were plated at 2.5 10
5 cells per well in a 6-well plate
and, following overnight attachment, transfected with 250ng of
pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C,
G13D, Q61H, L19F, K117N, A146T and R164Q. After 48h, cells
were harvested in 1ml of TRIzol reagent (Invitrogen) and total
RNA extracted according to the manufacturer’s instructions. RNA
was further purified using an RNeasy mini kit (Qiagen), eluted in a
final volume of 50ml RNAse-free dH20 and RNA quality and
concentration assessed with a Bioanalyzer 2100 using the RNA
6000 Nano LabChip Kit (Agilent). RNA labelling and microarray
hybridisation was carried out in collaboration with CXR
Biosciences, Dundee, UK. Briefly 1mg of total RNA sample was
amplified to generate complementary RNA (cRNA) and labelled
with cyanine 3-CTP (Cys3) using the QuickAmp labelling kit,
one-colour (Agilent). Labelled cRNA was hybridised to Agilent
4 44K Whole Mouse Genome Oligo Microarray slides, which
were scanned on an Agilent Microarray Scanner and images
processed using Agilent Feature Extraction Software v9.1.
Microarray data was analysed using the open-source software
Bioconducter 2.2. Lists of differentially expressed genes were
generated comparing each of the K-Ras mutants with empty vector
control using probes that exhibited an adjusted p value (false
discovery rate (FDR)) X0.05. Hierarchical clustering analysis was
carried out using ‘Cluster’ (open source clustering software) and
clusters visualised using Java TreeView.
K-Ras gene copy number assay
A new Taqman gene expression assay to evaluate K-Ras gene copy
number was designed, in which K-Ras copy number was compared
with the endogenous control gene RNAse P (copy number 2).
K-Ras was amplified from genomic DNA extracted from normal
and tumour tissues (n¼96 normal/tumour pairs) from our
colorectal patient series (Smith et al, 2002) with the oligonucleo-
tide primers 50-TTTAATACTTTTTATGTATTTCAGGGTGTTG-30
(300nM)a n d5 0-TTACCATCTTTGCTCATCTTTTCTTTAT-30 (300nM)
and Taqman probe 50-FAM-TGATGCCTTCTATACATTAGTTCGA
GAAATTCGAAAA-TAMRA-30 (100nM), and expression compared
with RNAse P by the comparative Ct method, according to the
manufacturer’s instructions (Applied Biosystems, Warrington, UK).
Fluorescent in-situ hybridisation (FISH) analysis
Sections (4mM) of formalin-fixed paraffin-embedded tumour tissue
were provided by Tayside Tissue Bank on positively charged
slides, which had been baked overnight at 561C. Sections were
deparaffinised using an automated protocol on a Vysis VP2000
processor, placed into a coplin-containing pre-warmed pre-
treatment solution (Vysis, Maidenhead, Kent, UK) and incubated
at 801C for 30min. Slides were then washed at room temperature
in water for 1min, before two 5min washes in 2 SSC before
digestion with protease buffer at 371C for 65min. Following
digestion, slides were washed three times in 2 SSC for 2min,
before sequential washes in 70, 85 and 100% ethanol for 2min each
at room temperature and dried on a 371C block. Meanwhile, 1ml
chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1ml
chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and
9ml LSI–WCP hybridisation buffer (Vysis) was mixed together for
each slide and pipetted onto a 22 22mm coverslip which was
Table 1 Site-directed mutagenesis (SDM) primers for Kirsten-Ras (K-Ras) mutation generation
Primer name Primer sequence
G12V SDM Forward 50-GTGGTGGGCGCTGTTGGCGTGGGAAAGAG-30
G12V SDM Reverse 50-CTCTTTCCCACGCCAACAGCGCCCACCAC-30
G12D SDM Forward 50-GTGGTGGGCGCTGATGGCGTGGGAAAGAG-30
G12D SDM Reverse 50-CTCTTTCCCACGCCATCAGCGCCCACCAC-30
G13D SDM Forward 50-GTGGGCGCTGGAGACGTGGGAAAGAGTG-30
G13D SDM Reverse 50-CACTCTTTCCCACGTCTCCAGCGCCCAC-30
Q61H SDM Forward 50-CGACACAGCAGGTCATGAGGAGTACAGTGC-30
Q61H SDM Reverse 50-GCACTGTACTCCTCATGACCTGCTGTGTCG-30
L19F SDM Forward 50-GTGGGAAAGAGTGCCTTCACCATCCAGCTGATC-30
L19R SDM Reverse 50-GATCAGCTGGATGGTGAAGGCACTCTTTCCCAC-30
K117N SDM Forward 50-CCTATGGTCCTAGTAGGAAATAACTGTGATTTGCCTTC-30
K117N SDM Reverse 50-GAAGGCAAATCACAGTTATTTCCTACTAGGACCATAGG-30
A146T SDM Forward 50-CCTTTTATTGAAACATCAACAAAGACAAGACAGGGTGTTGATG-30
A146T SDM Reverse 50-CATCAACACCCTGTCTTGTCTTTGTTGATGTTTCAATAAAAGG-30
R164Q SDM Forward 50-CATTAGTTCGAGAAATTCAAAAACATAAAGAAAAGATGAGCAAAGATGG-30
R164Q SDM Reverse 50-CCATCTTTGCTCATCTTTTCTTTATGTTTTTGAATTTCTCGAACTAATG-30
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splaced onto a region of the slide containing tumour tissue and placed
onto a heat block at 751C for 5min to co-denature the probes and
tumour tissue. Rubber cement was then applied to seal the coverslips
and slides placed into a humidified hybridisation chamber in a 371C
incubator overnight. The next morning, coverslips were removed and
slides placed into 0.4 SSC at 721Cf o r9 0sa n dt r a n s f e r r e dt o2 SSC
containing 0.005% Tween for 30s before being left to dry in the dark.
In all, 20ml of DAPI stain was then applied to coverslips, which were
then gently applied to each slide and, after removing air bubbles, sealed
with clear nail varnish. Slides werea n a l y s e do na ne p i f l u o r e s c e n c e
microscope (Olympus BX60), where probe signals from 20 different
cells in three different regions of the tumour tissue were counted and
the average number of probe signals and s.d. calculated.
RESULTS
Identification of new K-Ras mutations
We have previously described K-Ras mutations at codons 12, 13
and 61 in a series of 106 unselected colorectal tumours
(Smith et al, 2002). Our K-Ras mutation analysis was performed
by direct sequencing of K-Ras exon 1 (codons 12 and 13) and exon
2 (codon 61), and would therefore have detected any additional
mutations in these exons. Codon 12 mutations were detected in 23
tumours (21.7%) and codon 13 mutations in 6 tumours (5.7%),
whereas no codon 61 mutations were detected. Mutations at codon
19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single
tumours (Table 2).
To identify additional K-Ras mutations, and to establish the
relative frequencies of individual K-Ras mutations in human
colorectal tumours, we used WAVE analysis followed by direct
sequencing to screen the same tumour series for mutations in
K-Ras exon 3 and exon 4B, the most common exon 4 splice variant.
Four additional sequence changes were identified – an A to C
change (Lys to Asn substitution) at codon 117, a G to A change
(Ala to Thr substitution) at codon 146, a G to A change (Arg to
Gln substitution) at codon 164 and a ‘silent’ C to T nucleotide
substitution, which did not alter the aspartic acid residue at codon
173 (Table 2). Together, these K-Ras mutations and the B-Raf
V600E mutation increase overall Ras pathway mutation frequency
from 27.4 to 37.8%. The predicted localisation of each mutation in
the functional domains of the K-Ras protein is illustrated in
Figure 2.
To determine whether our reported sequence changes repre-
sented tumour-specific mutations or single-nucleotide polymor-
phisms (SNPs), genomic DNA from blood and tumour tissue was
compared. Sequence changes at codons 19, 117, 146 and 164 were
only detected in tumour DNA, whereas the codon 173 sequence
change was detected in both blood and tumour DNA, and therefore
represented a SNP (Table 2).
To determine the frequencies of the codon 117, 146 and 164
K-Ras mutations and the codon 173 SNP, PCR–RFLP assays were
designed to permit rapid screening of blood and tumour DNA
(Appendix A). Like the codon 19 mutation, the codon 117 and
codon 164 mutations were found in single tumours, whereas the
codon 146 mutation was found in 7 out of 106 (6.5%) of tumours.
No tumours with codon 19, 117, 146 or 146 mutations had
additional K-Ras mutations in codons 12, 13 or 61. The codon 173
SNP was found in 39 individuals, predicting an allele frequency of
18.2%. As this SNP did not lead to an amino acid substitution in
the K-Ras protein, it was not analysed further.
Comparison of phenotypes associated with hotspot and
new K-Ras mutations
Focus formation assays Phenotypes associated with the various
K-Ras mutations have previously not been systematically eval-
uated. To compare the transformation potential of the K-Ras
mutants, therefore, NIH3T3 cells were transiently transfected with
plasmids expressing wt K-Ras and the K-Ras mutations G12V,
G12D, G13D, Q61H, L19F, K117N, A146T and R164Q. Equivalence
of plasmid loading was assessed spectrophotometrically and by
western blotting for K-Ras (data not shown). Cells were stained
with crystal violet and foci counted 21 days after transfection, as
G12 Q61 L19 K117
Hypervariable
region
GTP binding Effector binding Switch 2: GEF interaction
￿ Hotspot K-Ras mutations ￿ Novel K-Ras mutations
R173
￿ K-Ras SNP
G13
Switch I:Effector/GAP interaction
R164 A146
Figure 2 Location of novel and hotspot Kirsten-Ras (K-Ras) mutations. The location of new (red) and hotspot (blue) K-Ras mutations are illustrated on a
representation of the K-Ras protein sequence, together with the position of the novel K-Ras single-nucleotide polymorphism (SNP) (black). Putative GTP
and effector binding sites and GAP and GEF interaction domains are highlighted.
Table 2 Frequencies of hotspot and novel mutations in Kirsten-Ras
(K-Ras) in colorectal tumours
Mutation
Nucleotide
change
Amino acid
change
Frequency
(%)
K-Ras
(A) Hotspot codon mutations
Codon
12 23/106 (21.7%)
G-4AG l y 12Ser 4/106 (3.8%)
G-4CG l y 12Ala 3/106 (2.8%)
G-4TG l y 12Cys 2/106 (1.9%)
G-4TG l y 12Val 6/106 (5.7%)
G-4CG l y 12Arg 1/106 (o1%)
G-4AG l y 12Asp 7/106 (6.6%)
13 G-4AG l y 13Asp 6/106 (5.7%)
61 None detected None detected 0/106
Mutation total 29/106 (27.4%)
(B) Novel codon mutations
Codon
19 G-4T Leu19Phe 1/106 (o1%)
117 A-4C Lys117Asn 1/106 (o1%)
146 G-4A Ala146Thr 7/106 (6.6%)
164 G-4A Arg164Gln 1/106 (o1%)
173
a T-4C No change 39/106 (36.8%)
New mutation total 39/106 (36.8%)
B-Raf
Codon
600 T-4A Val600Glu 1/106 (o1%)
Final mutation total 40/106 (37.8%)
aThe sequence change at codon 173 is a single-nucleotide polymorphism, not a
tumour-specific mutation.
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sdescribed in Materials and Methods (Figure 3). No foci were
observed in untransfected cells or in cells transfected with wt
K-Ras, whereas abundant foci were seen with each hotspot K-Ras
mutation (Figure 3A). Codon 12 mutations had slightly greater
transforming potential than codon 13 mutations and consistently
greater transforming potential than the codon 61 Q61H mutation
(Figure 3C). After transfection of additional K-Ras mutations,
significant focus formation was observed for codon 117 and 146
mutations (Figure 3B). In contrast, the codon 164 mutation was
phenotypically equivalent to wt K-ras with no evidence of foci
formation and the codon 19 mutation generated low but consistent
numbers of isolated foci (Figure 3C).
Ras activating assays To assess which K-Ras mutations were in
the active GTP-bound conformation, a Raf-1 binding assay was
carried out as described in Materials and Methods. Raf-1
selectively binds GTP-bound Ras (rather than the inactive
GDP-bound form) which, following immunoprecipitation, can be
visualised by western blotting. Figure 4 illustrates the results of our
analysis where, consistent with our focus formation experiments,
the K-Ras G12V and L19F, K117N and A146T mutations are clearly
in the active GTP-bound conformation. In contrast, the R164Q
mutation, like wt K-Ras, was not GTP-bound.
RNA transcription-profiling experiments To further compare and
contrast the phenotypes associated with each of the K-Ras mutants,
transcription-profiling experiments were carried out as described
in Materials and Methods. Hierarchical clustering analysis revealed
the presence of two major gene clusters, ‘cluster 1’ containing the
G12V, G12C and G12D mutants and ‘cluster 2’ containing G13D,
A146T, K117N, R164Q and L19F (Figure 5). It is interesting to note
that the codon 12 mutants were most similar to wt K-Ras, whereas
the K117N and A146T mutants clustered with the activating codon
13 and codon 61 hotspot mutants. The L19F and R164Q mutants
formed a subcluster within cluster 2 suggesting, consistent with
our foci formation data, that these mutants are phenotypically
distinct from the G13D, A146T and K117N mutants. The presence
of L19F in cluster 2 is consistent with our Ras GTPase assay data
whereas, in contrast, our experimental data for R164Q predicted a
‘wt’ Ras phenotype. The presence of R164Q in cluster 2, rather than
in cluster 1 with wt K-Ras was therefore initially surprising,
but suggests that the R164Q mutation also has an ‘activating’
phenotype, albeit attenuated relative to the other mutations
studied.
To further investigate the phenotypes associated with each of
the K-Ras mutants, the expression of a diverse selection of genes
associated a variety of cellular processes including signal
transduction, cytoskeleton remodelling and cell adhesion was
compared. Although further analysis of this complex dataset,
including composite analysis of biological pathways and processes
is ongoing and will be discussed in more detail in a future
manuscript, representative examples of genes showing differential
expression following the introduction of each K-Ras mutant are
summarised in Table 3.
pEF.6
WT
G12V
G12D
G13D
Q61H
WT
G12V
L19F
K117N
A146T
R164Q
–20
0
20
40
60
80
100
K-Ras plasmid
Number of foci >
5 mm
None R164Q A146T K117N L19F Q61H G13D G12D G12V WT
Figure 3 Focus formation assays. NIH3T3 cells were transfected with pEF.6 or plasmids containing wt or mutant K-Ras and foci visualised after crystal
violet staining. (A) Cells transfected with empty vector or wt K-Ras were compared with previously described hotspot mutations. (B) The transforming
potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras. All experiments were performed
in duplicate and each set of transfections was repeated three times. (C) The combined results of all transfections, wherein total foci counts are presented ±
SD are illustrated.
pEF.6
(B) K-Ras
(C) -actin
(A) Active Ras 21 kD
21 kD
43 kD
R164Q A146T K117N L19F G12V WT
Figure 4 Ras GTPase activating assays. Ras GTPase activating assays
were carried out for each of the novel Kirsten-Ras (K-Ras) mutations and
western blotting used to assess the expression of (A) active GTP-bound
K-Ras (B) total K-Ras and (C) b-actin (loading control). The K-Ras G12V
construct was included as a positive control for K-Ras protein in the active
GTP-bound conformation.
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sConsistent with our hierarchical clustering analysis, introduc-
tion of the R164Q mutation led to relatively few changes in gene
expression or showed reduced pathway activation compared with
the other mutants studied. However, there were examples of genes
that were induced by all of the mutants studied, including the
protein tyrosine phosphatase Ptpre and the Rho GTPase activating
protein Arhgap6, and multiple examples of genes induced or
repressed by all of the mutants with the exception of R164Q. These
included the MAPK phosphatases DUSP4 and DUSP6, Ereg, Hbegf
and Btc, all involved in EGFR binding, the Rho guanine-exchange
factor NGEF, cell adhesion molecule Ceacam 1 and plasminogen
activator inhibitor Serpinb2. Consistently, the novel A146T and
K117N mutants (and, to a lesser extent, the L19F mutant) clustered
with and influenced gene expression similarly to the previously
described activating G13D and Q61H ‘hotspot’ mutations.
Of particular interest were genes, for example, Vegfa, Pak3,
Pim1 and EII2 which were differentially expressed by cluster 1
but not cluster 2 mutants, genes, for example, Spry4, Igf1R,
Creb1 and Tcf4 which were differentially expressed by
cluster 2 mutants, and additional genes, for example, Jun, E2F2,
Mmp3 and Glut-1 which were differentially regulated by each
mutant studied.
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Figure 5 Hierarchical clustering analysis. RNA transcription profiling analysis was carried out as described in Materials and Methods. Lists of differentially
expressed genes were generated comparing each of the Kirsten-Ras (K-Ras) mutants with empty vector control using probes that exhibited an adjusted
P-value (false discovery rate (FDR)) X0.05. Following hierarchical clustering analysis, gene clusters were represented on a heat map, where upregulated
genes are highlighted in green and downregulated genes highlighted in red.
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To investigate whether altered K-Ras activity could additionally
result from gene amplification, a K-Ras gene copy number assay
was designed and carried out as described in Materials and
Methods and K-Ras copy number compared in normal and tumour
tissues. In total, 2 of the 96 tumour pairs analysed (2.1%) showed
tumour-specific copy number increases (Figure 6), one (study code
1264, wt K-Ras) with 4 tumour copies of K-Ras and the other
(study code 1233, wt K-Ras) with 27 copies of the K-Ras
gene. Assay reproducibility and linearity was demonstrated from
the analysis of standard curves generated by serial dilutions of a
wide concentration range of input genomic DNA (data not shown).
K-Ras gene amplification was confirmed by FISH analysis as
described in Materials and Methods (Figure 7). Figures 7A and B
illustrate chromosome metaphase spreads confirming FISH probe
specificities for chromosomes 12p and 12q, respectively, whereas
Figures 7C and D show representative colorectal tumour FISH
analysis. Figure 7C illustrates a tumour sample (study code 1271)
in which the K-Ras gene is not amplified (red fluorescence¼green
fluorescence), whereas Figure 7D illustrates a colorectal tumour
(study code 1264) with K-Ras gene amplification (red fluores-
cence4green fluorescence). Signals from the red 12p12.1 probe in
tumour 1264 appear as a cluster of bright dots forming a line
which is suggestive of a homogeneously staining region (HSR), a
chromosomal region which is amplified either on the original
chromosome or on another chromosome, as opposed to double
minutes where the amplified gene is located in extra-chromosomal
circular DNA molecules.
Table 3 Summary of genes differentially expressed by the different Kirsten-Ras (K-Ras) mutations relative to NIH3T3 cells mock transfected with pEF
vector
Fold change
Cluster 1 Cluster 2
Gene Gene function G12V G12C G12D G13D A146T K117N Q61H R164Q L19F
Signal transduction
DUSP4 MAPK phosphatase activity 2.4 4.3 3.1 3.3 2.9 3.2 2.9 ND 2.9
DUSP6 Phosphoprotein phosphatase activity 2.8 3 2.5 2.2 2.2 2.6 2.8 ND 1.9
Ptpre Protein tyrosine phosphatase activity 3.2 5.1 3.8 5.2 4.0 5.6 4.4 2.7 4.5
Spry4 Protein binding ND ND ND 7.0 5.9 4.1 5.6 ND 4.4
Ereg EGFR binding 7.5 11.1 7.9 7.0 7.0 7.3 8.6 ND 6.2
Hbegf EGFR binding 2.3 3.6 2.8 2.6 2.2 2.7 2.7 ND 2.2
Btc EGFR binding 4.2 5.3 5.1 4.5 4.5 3.9 5.8 ND 4.1
Vegfa Growth factor activity 1.8 2.3 1.8 ND ND ND ND ND ND
Igf1R Protein tyrosine kinase activity ND ND ND 2.7 2.3 2.3 2.8 ND 2.7
Jun Transcription factor 2.0 2.0 1.8 ND ND 1.4 1.4 ND ND
E2F2 Transcription factor 3.3 4.2 3.5 2.4 ND ND 2.3 ND ND
Creb1 Transcription factor ND ND ND 2.3 2.0 2.0 2.3 ND 2.8
Wnt5A Receptor binding 2.3 2.8 ND 2.5 2.8 2.2 ND ND 2.4
TCF4 Transcription factor ND ND ND 2.7 2.5 3.2 ND 2.6 3.2
Cytoskeleton remodelling
Arhgap6 Rho GTPase activator activity 8.7 10.5 4.6 10.7 9.2 9.7 13.2 3.0 7.2
NGEF Rho guanine-exchange factor activity 3.5 9.1 5.5 3.9 3.8 5.0 4.0 ND 3.0
Cell adhesion
MMP3 Metalloendopeptidase activity 3.5 2.3 ND 2.5 2.9 3.3 3.4 ND ND
Ceacam1 Cell adhesion 17.8 29.9 21.1 19.9 20.4 30.0 27.5 ND 15.6
G-protein signalling
GNAQ Signal transducer activity ND ND ND 1.8 ND 1.5 1.7 ND 1.8
Gna11 Signal transducer activity  1.5 ND ND  1.6  1.9  1.5  1.9  1.6  1.7
Immune response
Ccl2 Cytokine 3.2 2.8 2.2 1.9 2.0 2.2 2.0 ND ND
Protein kinases
Abl1 Tyrosine-protein kinase  1.6  1.5 ND  1.6  1.6  1.8  2.0  1.6  1.8
Pak3 Protein serine/threonine kinase  1.6  1.8  1.7 ND ND ND ND ND ND
Pim1 Protein serine/threonine kinase 1.9 1.6 1.6 ND ND ND ND ND ND
Cell survival
Serpinb2 Serine-type endopeptidase inhibitor activity 12.4 20.7 11.7 15.8 19.1 18.5 18.5 ND 13.7
Transcription
Ell2 RNA polymerase II transcription elongation
factor activity
3.1 2.8 2.8 ND ND ND ND ND ND
Metabolism/glycolysis
Glut-1 Glucose transport 2.0 1.8 1.6 1.8 ND 1.5 1.5 ND ND
Abbreviation: ND¼statistically significant fold change not detected.
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sDISCUSSION
Recent clinical data has shown a compelling association between
K-Ras and B-Raf mutation status and response to EGFR blockade
by cetuximab and panitumumab in the treatment of metastatic
colorectal tumours (Benvenuti et al, 2007; Khambata-Ford et al,
2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008).
K-Ras mutations in colorectal tumours have been extensively
documented, where recent meta analysis of more than 3000
tumours estimates an average K-Ras mutation frequency of 34.8%
(Andreyev et al, 2001). This and the majority of previous analyses
were, however, limited to codons 12 and 13, whereas only a
minority of studies have additionally analysed codon 61. Although
additional K-Ras mutations have been reported outwith these
‘hotspot’ codons, to our knowledge, there has been no systematic
analysis of K-Ras mutation frequency in human colorectal
tumours. Our use of ‘WAVE’ denaturing HPLC (dHPLC) analysis
(Kuklin et al, 1997) allowed us to carry out a rapid, systematic
analysis of the entire K-Ras coding sequence to identify colorectal
tumours with sequence changes, the nature which were sub-
sequently confirmed by conventional dideoxy sequencing.
Our data clearly demonstrates that K-Ras mutations in human
colorectal tumours are likely to be significantly underestimated if
only hotspot codons are analysed. Indeed, current mutation
screening tests based on the hotspot codons 12 and 13 are likely
to result in the mis-classification of up to one-third of patients.
Although mutations at codons 19, 117 and 164 are relatively rare
events, our data suggests that each K-Ras mutation may
differentially influence treatment response. We would therefore
recommend the adoption of comprehensive K-Ras mutation
profiling, or at least the routine inclusion of the codon 146
mutation, for patient selection for cetuximab and related therapies.
Current data from the COSMIC database, which summarises
literature data and the ongoing Sanger cancer-genome project
describes 29 K-Ras colorectal tumour mutations outwith codons
12, 13 and 61, and more than 11800 mutations at these hotspot
codons (http://www.sanger.ac.uk/genetics/CGP/), but does not
describe associated phenotypes. Consistent with our own data,
codon 146 was the most frequently mutated of the mutations
described. K-Ras codon 146 mutations have been described in a
human colorectal tumour cell line (Higashi et al, 1990), in mice
with thymic lymphomas (Sloan et al, 1990) and in a single human
colorectal tumour case report (Orita et al, 1991). In more detailed
molecular profiling studies, codon 146 mutations were described
in 4% of two independent colorectal tumour series from Hong
Kong and the United States of America (Edkins et al, 2006) and in
chronic myelomonocytic leukaemia (Gelsi-Boyer et al, 2008; Tyner
et al, 2009). Consistent with our own data, Tyner et al (2009)
reported an oncogenic phenotype associated with the K-Ras 146
mutation in leukaemia and Loupakis et al (2009) have recently
reported that a patient with metastatic colorectal cancer with
a K-Ras 146 mutation was resistant to cetuximab.
There is only a single report of K-Ras codon 19 mutations in
human colorectal tumours (Akagi et al, 2007), in which in vitro
elevation of active Ras-GTP levels, anchorage-independent growth
and increased tumourigenicity in nude mice was demonstrated.
A codon 19 mutation has additionally been described in H-Ras in a
human pituitary carcinoma metastases (Pei et al, 1994). There are
two recent reports of codon 117 mutations – the first in K-Ras in
human colorectal tumours (Wojcik et al, 2008) and the second in
H-Ras, associated with activation of the RAS–MAPK pathway and
the mental retardation Costello syndrome (Denayer et al, 2008). It
is interesting to note that Costello syndrome has been associated
with increased cancer predisposition (Gripp, 2005). There are no
reports of K-Ras 164 mutations, and mutations at this codon were
not identified by Sanger cancer genome project investigators.
Recent clinical data convincingly associates response to anti-
EGFR therapies with K-Ras mutation status in patients with
metastatic colorectal cancer where, logically, response is preferen-
tially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti
et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008;
Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van
Cutsem et al, 2009) which retain the ability to respond to EGFR
blockade. Our description of K-Ras gene amplification in a subset
of wt tumours is of particular interest in this regard as increased
K-Ras gene copy number may lead to a more active ‘mutation’-like
phenotype. Experiments to investigate this possibility are currently
underway in our laboratory.
It is interesting to note that our transcription profiling analysis
revealed some similarities but many marked differences in gene
expression following the introduction of the individual K-Ras
mutants. We found that the codon 117 and the common codon 146
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Figure 6 Kirsten-Ras (K-Ras) gene copy number assay. A novel K-Ras
gene copy number assay was designed as described in Materials and
Methods and used to screen genomic DNA samples extracted from 96
paired normal (N) and colorectal tumour (T) tissues. Representative results
from six normal/tumour pairs are illustrated, highlighting increased copy
number in samples 1233 and 1264.
Figure 7 FISH analysis. Chromosome metaphase spreads were
hybridised with FISH probes for (A) chromosome 12p (red) and
(B) chromosome 12q (green) to confirm probe specificity and FISH
analysis performed as described in Materials and Methods. Representative
colorectal tumour sections (C) without and (D) with a K-Ras gene
amplification are illustrated.
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tions at codons 13 and 61, highlighting differences in individual
mutation phenotypes. Our analysis of K-Ras induced gene
expression identified a number of genes previously associated
with K-Ras signalling, for example the MAPK dual specificity
phosphatases DUSP4 and DUSP6. DUSPs are key regulators of the
balance between kinase pathway activation and inactivation, and
have previously been reported to be upregulated in an adaptive
response, creating a negative feedback loop following MAPK
pathway activation (Keyse, 2008). Consistent with our own data,
DUSP4 expression has previously been shown to be increased in
pancreatic tumours with K-Ras mutations (Yip-Schneider et al,
2001) and DUSP6 expression increased in a variety of tumour
types with mutations in Ras or Raf pathway genes (Croonquist
et al, 2003; Warmka et al, 2004; Bloethner et al, 2005). Of particular
interest, however, was our observation that certain signalling
cascades, including those mediated by Igf1 and Vegf, were
differentially activated by cluster 1 and cluster 2 K-Ras mutants,
suggesting that not only the presence but the specific molecular
characteristics of individual K-Ras mutations may be important
determinants of both tumour progression and treatment response.
For example, recent data suggests that glucose deprivation can
promote the acquisition of K-Ras mutations in human tumours
and reports upregulation of the glucose transporter GLUT-1 in
K-Ras mutant tumours (Yun et al, 2009). Our data confirms this
hypothesis, but shows GLUT-1 induction restricted to the codon
12, 13, 61 and 117 mutations, with no change in GLUT-1
expression associated with the introduction of codon 19, 146 or
164 mutations, again reflecting phenotypic heterogeneity.
Current clinical data is sufficiently compelling that K-Ras
mutation testing to facilitate the selection of patients most likely
to benefit from anti-EGFR therapy is increasingly recommended in
clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and
has resulted in a recent formal recommendation from the National
Comprehensive Cancer Network that patients with K-Ras tumour
mutations should not be treated with cetuximab or panitumumab
(McNeill, 2008). There is increasing interest in the identification
of prognostic molecular markers, which may be used to select
the most appropriate patients for adjuvant chemotherapy or to
identify colorectal cancer patients at increased risk of disease
progression. Although the clinical implications of non-hotspot
K-Ras mutations requires further validation both as prognostic
markers and therapeutic targets, our data suggests that future
analysis of K-Ras mutations and quantitation of mutation burden in
colorectal tumours should not be limited to previously described
mutation hotspots and should additionally consider the unique
molecular signatures associated with individual K-Ras mutations.
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Appendix 1
Kirsten-Ras (K-Ras) mutation detection and restriction fragment
length polymorphism (RFLP) analysis of mutation frequencies
K-Ras Exon 3 and Exon 4 mutation detection
Mutations in exons 3 and 4 of the K-Ras gene were identified using
the Transgenomic WAVE denaturing HPLC system. PCR products
for WAVE analysis were generated using the Expand High Fidelity
PCR system (Roche, Welingkar garden, UK) incorporating Taq
polymerase with enhanced proofreading activity. A 200bp PCR
product encompassing K-Ras exon 3 was generated using the
oligonucleotide primers 50-TTCTTTCCCAGAGAACAAATTAA-30
and 50-AGATCTGTATTTATTTCAGTGTTACTTACC-30. Similarly,
a 261bp PCR product encompassing K-Ras Exon 4b
was generated using the oligonucleotide primers 50-TACTT
TTTATGTATTTCAGGGTGTTG-30 and 50-GCTAACAGTCTGC
ATGGAGC-30.
Assay conditions (acetonitrile gradient and temperature profile)
were optimised for WAVE analysis of each PCR fragment using
Transgenomic WAVEMAKER 4.1 software, according to the
manufacturer’s instructions. K-Ras exon 3 was analysed at 551C
with an initial concentration of 51% Buffer B (0.1 M TEAA, 25%
acetonitrile) and exon 4 at 551C with an initial concentration of
54% Buffer B. All samples were denatured and cooled slowly to
room temperature before WAVE analysis to maximise hetero-
duplex formation.
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The K-Ras mutations detected by WAVE analysis were confirmed
by direct sequencing of PCR products. This analysis was
performed by the DNA analysis facility, Department of Molecular
and Cellular Pathology, Ninewells Hospital and Medical School,
Dundee DD1 9SY, UK, using 16 capillary ABI 3100 Genetic
Analysers (Applied Biosystems). Before sequencing, all PCR
products were purified using QIAquick PCR purification kits
(Qiagen), according to the manufacturer’s instructions. All
sequences obtained were aligned with previously published
sequences (NCBI Genbank Accession Numbers L00047 and
L00049 for K-Ras exons 3 and 4b, respectively); the presence
and nature of each mutation was confirmed by repeat PCR and
sequencing.
RFLP analysis of K-Ras codon 117 mutations
To permit rapid identification of the K-Ras codon 117 mutation, a
PCR–RFLP assay was designed where the presence of the mutation
created a recognition site for the restriction enzyme Bsr S1.
A 288bp PCR product was amplified using the primers 50-GATCT
TTTGAGAGAGATACAAGGTTTC-30 and 50-TGTTCTAGAAGGCA
AATCACA-30. Following PCR amplification, PCR products were
digested with Bsr S1 for 2h at 651C and analysed on 8%
polyacrylamide gels, run in 1  TBE buffer at 200V for 2h. Gels
were stained with ethidium bromide and DNA bands visualised on
a UV transilluminator. Samples without the K-Ras codon 117
mutation were resistant to digestion and produced a single band of
288bp, whereas samples homozygous for the codon 117 mutation
were digested to produce bands of 271 and 17bp. Heterozygous
samples produced bands of 288, 271 and 17bp. Band sizes were
determined by comparison with FX174 DNA size markers
(Promega).
RFLP analysis of K-Ras codon 146 mutations
Similarly, a PCR-RFLP assay was designed to identify the K-Ras
codon 146 mutation, where the presence of the mutation created a
recognition site for the restriction enzyme Mse I. A 197bp PCR
product was amplified using the primers 50 TGG AAT TCC TTT
TAT TGA AAC ATC A 30 and 50 GAT TAA GAA GCA ATG CCC
TCT C 30. Following PCR amplification, PCR products were
digested with Mse1 for 2h at 371C and analysed on 8%
polyacrylamide gels as described above. Samples without the
K-Ras codon 146 mutation were digested to produce bands of 101,
91 and 5bp, whereas samples homozygous for the codon 146
mutation produced bands of 91, 78, 23 and 5bp. Heterozygous
samples produced bands of 101, 91, 78, 23 and 5bp.
RFLP analysis of K-Ras codon 164 mutations
The presence of the codon 164 mutation was confirmed using a
novel RFLP assay, wherein the presence of the mutation destroyed
a recognition site for the restriction enzyme BstBI. A 261bp PCR
product was generated as described above for K-Ras exon 4B
mutation detection. After PCR amplification, PCR products were
digested with BstBI for 2h at 651C and analysed on 2% agarose
gels. Samples without the codon 164 mutation were digested to
produce bands of 203 and 58bp, whereas samples homozygous for
the mutation produced a single band of 261bp. Heterozygous
samples produced bands of 261, 203 and 58bp.
RFLP analysis of K-Ras codon 173 single-nucleotide
polymorphism (SNP)
The codon 173 SNP was detected using a novel RFLP assay, where
the presence of the mutation destroyed a recognition site for the
restriction enzyme BccI. A 261bp PCR product was generated as
described above for K-Ras exon 4B mutation detection. After PCR
amplification, PCR products were digested with BccI for 2h at 371C
and analysed on 2% agarose gels. Samples without the codon 173
SNP were digested to produce bands of 173 and 88bp, whereas
samples homozygous for the codon 173 SNP produced a single
band of 261bp. Heterozygous samples produced bands of 261, 173
and 88bp.
RFLP analysis of B-Raf V599E mutation
The B-Raf V599E mutation was detected using a novel RFLP assay,
where the presence of the mutation destroyed a recognition site for
the restriction enzyme TspRI. A 224bp PCR product was amplified
using the primers 50-TCATAATGCTTGCTCTGATAGGA-30 and
50-GGCCAAAAATTTAATCAGTGGA-30 in a 50ml reaction con-
taining 1  PCR buffer (Promega), 1.25mM MgCl2, 200mM dNTPs,
300nM primers, 6% DMSO and 1.5U of Taq polymerase in a PCR
as described above. After PCR amplification, PCR products were
digested with TspR1 for 2h at 371C and analysed on 8%
polyacrylamide gels as described above. Samples without the
B-Raf V599E mutation were digested to produce bands of 124, 78
and 22bp, whereas samples homozygous for the V599E mutation
produced bands of 202 and 22bp. Heterozygous samples produced
bands of 202, 124, 78 and 22bp.
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